Last year, Synageva Biopharma Corp. went to Alexion Pharmaceuticals Inc. in one of the year's biggest buyouts – an $8.4 billion cash and stock deal notable for its whopping 140 percent premium. With the ink barely dry on that deal, the former execs of the rare disease firm decided they were ready for another round, regrouping to create new startup Kiniksa Pharmaceuticals.